{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:54:51Z","timestamp":1781632491235,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Narcolepsy is a chronic neurological disorder treated with medications that promote wakefulness. Pitolisant, a histamine H3 receptor inverse agonist, is used to reduce excessive daytime sleepiness. Although pitolisant clinical trials describe mainly mild adverse effects, severe psychiatric reactions have been reported, yet detailed clinical descriptions remain limited. This case describes a first-onset manic episode with psychotic features shortly after pitolisant initiation in an adult without any psychiatric history, highlighting a rare but clinically significant potential reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 51-year-old woman newly diagnosed with narcolepsy type 2 without psychiatric history began treatment with pitolisant, titrated up to 36\u00a0mg daily. She did not use recreational substances and had hypothyroidism well-managed with levothyroxine. After swift initial improvement in wakefulness, she developed behavioral changes including heightened sociability, impulsivity, and decreased need for sleep. Within weeks, the condition progressed to a severe manic state characterized by paranoid ideation, auditory hallucinations, and disinhibition. Primary care treatment with low-dose sedatives demonstrated minimal effect, resulting in referral for involuntary psychiatric admission. Comprehensive neurological, infectious, metabolic, and autoimmune evaluations were without remarks. Pitolisant was discontinued upon admission. Management included high-dose olanzapine, lorazepam, and subsequently electroconvulsive therapy, after which the manic episode resolved. She was stabilized on risperidone and olanzapine, which were gradually tapered as her condition improved. At follow-up two months after discharge, she remained euthymic and was referred to primary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case demonstrates a severe manic episode with psychotic symptoms emerging shortly after pitolisant initiation in an adult without prior psychiatric vulnerability. The temporal association, absence of alternative medical explanations, and resolution after drug discontinuation suggest a possible medication-related trigger. Clinicians prescribing pitolisant should closely monitor for early behavioral or mood changes, particularly during dose increases, and recognize that significant psychiatric reactions may occur even in individuals with no prior mental health history.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-04661-7","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T02:24:38Z","timestamp":1769653478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pitolisant-associated mania \u2013 a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Maximilian","family":"Zoltek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"\u00c5gren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"2","key":"4661_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","volume":"20","author":"CE Mahoney","year":"2019","unstructured":"Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The Neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20(2):83\u201393.","journal-title":"Nat Rev Neurosci"},{"issue":"6","key":"4661_CR2","doi-asserted-by":"publisher","first-page":"e13387","DOI":"10.1111\/jsr.13387","volume":"30","author":"CLA Bassetti","year":"2021","unstructured":"Bassetti CLA, Kallweit U, Vignatelli L, Plazzi G, Lecendreux M, Baldin E, et al. European guideline and expert statements on the management of narcolepsy in adults and children. J Sleep Res. 2021;30(6):e13387.","journal-title":"J Sleep Res"},{"issue":"1","key":"4661_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.sleep.2010.05.010","volume":"12","author":"S Overeem","year":"2011","unstructured":"Overeem S, van Nues SJ, van der Zande WL, Donjacour CE, van Mierlo P, Lammers GJ. The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency. Sleep Med. 2011;12(1):12\u20138.","journal-title":"Sleep Med"},{"issue":"4","key":"4661_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2869.2004.00422.x","volume":"13","author":"C Sturzenegger","year":"2004","unstructured":"Sturzenegger C, Bassetti CL. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res. 2004;13(4):395\u2013406.","journal-title":"J Sleep Res"},{"issue":"9","key":"4661_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","volume":"15","author":"CLA Bassetti","year":"2019","unstructured":"Bassetti CLA, Adamantidis A, Burdakov D, Han F, Gay S, Kallweit U, et al. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15(9):519\u201339.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"4661_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.sleep.2008.05.009","volume":"10","author":"WT Longstreth Jr","year":"2009","unstructured":"Longstreth WT Jr., Ton TG, Koepsell T, Gersuk VH, Hendrickson A, Velde S. Prevalence of narcolepsy in King County, Washington, USA. Sleep Med. 2009;10(4):422\u20136.","journal-title":"Sleep Med"},{"issue":"4","key":"4661_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-0404.2007.00930.x","volume":"117","author":"YK Shin","year":"2008","unstructured":"Shin YK, Yoon IY, Han EK, No YM, Hong MC, Yun YD, et al. Prevalence of narcolepsy- cataplexy in Korean adolescents. Acta Neurol Scand. 2008;117(4):273\u20138.","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"4661_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/sleep\/25.2.197","volume":"25","author":"MH Silber","year":"2002","unstructured":"Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in olmsted County, minnesota: a population-based study. Sleep. 2002;25(2):197\u2013202.","journal-title":"Sleep"},{"issue":"5","key":"4661_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/14656566.2018.1561861","volume":"20","author":"S de Biase","year":"2019","unstructured":"de Biase S, Gigli GL, Valente M. Important decisions in choosing the pharmacotherapy for narcoleptics. Expert Opin Pharmacother. 2019;20(5):483\u20136.","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"4661_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11940-016-0429-y","volume":"18","author":"L Barateau","year":"2016","unstructured":"Barateau L, Lopez R, Dauvilliers Y. Management of narcolepsy. Curr Treat Options Neurol. 2016;18(10):43.","journal-title":"Curr Treat Options Neurol"},{"issue":"17","key":"4661_CR11","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","volume":"31","author":"M Mieda","year":"2011","unstructured":"Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, Sakurai T. Differential roles of orexin receptor-1 and \u2013\u20092 in the regulation of non-REM and REM sleep. J Neurosci. 2011;31(17):6518\u201326.","journal-title":"J Neurosci"},{"issue":"9","key":"4661_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/sleep\/32.9.1127","volume":"32","author":"S Kantor","year":"2009","unstructured":"Kantor S, Mochizuki T, Janisiewicz AM, Clark E, Nishino S, Scammell TE. Orexin neurons are necessary for the circadian control of REM sleep. Sleep. 2009;32(9):1127\u201334.","journal-title":"Sleep"},{"issue":"2","key":"4661_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11910-011-0178-y","volume":"11","author":"T Kanbayashi","year":"2011","unstructured":"Kanbayashi T, Sagawa Y, Takemura F, Ito SU, Tsutsui K, Hishikawa Y, et al. The pathophysiologic basis of secondary narcolepsy and hypersomnia. Curr Neurol Neurosci Rep. 2011;11(2):235\u201341.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"4661_CR14","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1017\/neu.2025.20","volume":"37","author":"M Zoltek","year":"2025","unstructured":"Zoltek M, \u00c5gren R. Attention-deficit hyperactivity disorder drug search trends: a Scandinavian perspective. Acta Neuropsychiatr. 2025;37:e65.","journal-title":"Acta Neuropsychiatr"},{"issue":"11","key":"4661_CR15","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1097\/00004583-200111000-00006","volume":"40","author":"RS James","year":"2001","unstructured":"James RS, Sharp WS, Bastain TM, Lee PP, Walter JM, Czarnolewski M, et al. Double- blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry. 2001;40(11):1268\u201376.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"4661_CR16","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1176\/appi.ajp.20230329","volume":"181","author":"LV Moran","year":"2024","unstructured":"Moran LV, Skinner JP, Shinn AK, Nielsen K, Rao V, Taylor ST, et al. Risk of incident psychosis and mania with prescription amphetamines. Am J Psychiatry. 2024;181(10):901\u20139.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"4661_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/JCP.0000000000001631","volume":"43","author":"OH Jefsen","year":"2023","unstructured":"Jefsen OH, \u00d8stergaard SD, Rohde C. Risk of mania after methylphenidate in patients with bipolar disorder. J Clin Psychopharmacol. 2023;43(1):28\u201334.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"4661_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5152\/npa.2015.7160","volume":"52","author":"\u00d6 Ayta\u015f","year":"2015","unstructured":"Ayta\u015f \u00d6, Dilek Yalva\u00e7 H. Modafinil-Induced psychosis: A case report. Noro Psikiyatr Ars. 2015;52(1):99\u2013101.","journal-title":"Noro Psikiyatr Ars"},{"issue":"2","key":"4661_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40263-020-00703-x","volume":"34","author":"YN Lamb","year":"2020","unstructured":"Lamb YN, Pitolisant. A review in narcolepsy with or without cataplexy. CNS Drugs. 2020;34(2):207\u201318.","journal-title":"CNS Drugs"},{"issue":"4","key":"4661_CR20","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bph.15220","volume":"178","author":"T Yoshikawa","year":"2021","unstructured":"Yoshikawa T, Nakamura T, Yanai K. Histaminergic neurons in the tuberomammillary nucleus as a control centre for wakefulness. Br J Pharmacol. 2021;178(4):750\u201369.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"4661_CR21","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","volume":"12","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068\u201375.","journal-title":"Lancet Neurol"},{"issue":"1","key":"4661_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1124\/jpet.110.170134","volume":"336","author":"JS Lin","year":"2011","unstructured":"Lin JS, Sergeeva OA, Haas HL. Histamine H3 receptors and sleep-wake regulation. J Pharmacol Exp Ther. 2011;336(1):17\u201323.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4661_CR23","doi-asserted-by":"publisher","first-page":"e1161","DOI":"10.1002\/prp2.1161","volume":"12","author":"C Jiang","year":"2024","unstructured":"Jiang C, Qian J, Jiang X, Zhang S, Zheng J, Wang H. Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post-marketing safety. Pharmacol Res Perspect. 2024;12(1):e1161.","journal-title":"Pharmacol Res Perspect"},{"key":"4661_CR24","first-page":"2460492","volume":"2022","author":"MS Ontoso","year":"2022","unstructured":"Ontoso MS, Gonzalez RAP, Martinez IR, Garcia JMM. Clinical diagnosis of an autoimmune encephalitis presented as a manic episode with psychotic symptoms: A case report. Case Rep Psychiatry. 2022;2022:2460492.","journal-title":"Case Rep Psychiatry"},{"issue":"1","key":"4661_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.psym.2019.03.002","volume":"61","author":"M Restrepo-Martinez","year":"2020","unstructured":"Restrepo-Martinez M, Chacon-Gonzalez J, Bayliss L, Ramirez-Bermudex J, Fricchione GL, Espinola-Nadurille M. Delirious Mania as a Neuropsychiatric Presentation in Patients With Anti-N-methyl-D-aspartate Receptor Encephalitis. Psychosomatics. 2020;61(1):64\u20139.","journal-title":"Psychosomatics"},{"issue":"12","key":"4661_CR26","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1212\/WNL.0b013e3182a4a49c","volume":"81","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Iizuka T, Kawachi I, Bataller L, et al. Late-onset anti\u2013NMDA receptor encephalitis. Neurology. 2013;81(12):1058\u201363.","journal-title":"Neurology"},{"issue":"2","key":"4661_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04661-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04661-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04661-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:18:23Z","timestamp":1781630303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04661-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4661"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04661-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent has been obtained from the patient to publish this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent has been obtained from the patient to publish this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}